Achieve Life Sciences (ACHV) Research & Development (2010 - 2026)
Achieve Life Sciences (ACHV) recorded quarterly Research & Development of $3.0 million in Q1 2026, down 22.53% on a QoQ basis from $3.8 million in Q4 2025, and down 58.08% year-over-year from $7.1 million in Q1 2025.
Achieve Life Sciences (ACHV) Research & Development (2010 - 2026) Analysis & Trends
Achieve Life Sciences has disclosed Research & Development across 17 years of filings, most recently posting $3.0 million for Q1 2026.
- Quarterly Research & Development fell 58.08% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.8 million (down 30.51% YoY) and the FY2025 annual result came in at $23.0 million, up 0.64% from the prior year.
- Research & Development retreated to $3.0 million in Q1 2026, from $3.8 million in the prior quarter.
- Over five years, Research & Development peaked at $9.9 million in Q3 2022 and troughed at $2.1 million in Q4 2023.
- A 5-year average of $5.6 million and a median of $5.3 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development tumbled 75.46% — and 2024, when it surged 245.13%.
- Tracing ACHV's Research & Development over 5 years: stood at $8.6 million in 2022, then slumped by 75.46% to $2.1 million in 2023, then jumped by 245.13% to $7.3 million in 2024, then plunged by 47.37% to $3.8 million in 2025, then fell by 22.53% to $3.0 million in 2026.
- Business Quant data shows ACHV's Research & Development at $3.0 million in Q1 2026, $3.8 million in Q4 2025, and $5.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 1.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -2.30 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -58.00 Mn |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | 2.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.98 Mn |
| Dec 31, 2025 | 3.84 Mn |
| Sep 30, 2025 | 5.32 Mn |
| Jun 30, 2025 | 6.71 Mn |
| Mar 31, 2025 | 7.10 Mn |
| Dec 31, 2024 | 7.30 Mn |
| Sep 30, 2024 | 7.61 Mn |
| Jun 30, 2024 | 5.11 Mn |
| Mar 31, 2024 | 2.80 Mn |
| Dec 31, 2023 | 2.11 Mn |
| Sep 30, 2023 | 3.58 Mn |
| Jun 30, 2023 | 4.59 Mn |
| Mar 31, 2023 | 5.53 Mn |
| Dec 31, 2022 | 8.61 Mn |
| Sep 30, 2022 | 9.87 Mn |
| Jun 30, 2022 | 7.21 Mn |
| Mar 31, 2022 | 4.39 Mn |
| Dec 31, 2021 | 4.51 Mn |
| Sep 30, 2021 | 4.59 Mn |
| Jun 30, 2021 | 9.23 Mn |